Evidence map›Paper›PMID 36164552›Full record

ArticleFrontiers in cellular and infection microbiology2022

Occurrence of SARS-CoV-2 reinfections at regular intervals in Ecuador.

Rommel Guevara, Belén Prado-Vivar, Sully Márquez, Erika B Muñoz, Mateo Carvajal, Juan José Guadalupe, Mónica Becerra-Wong, Stefanie Proaño, Rosa Bayas-Rea, Josefina Coloma and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Single nucleotide variants in theFrontiers in cellular and infection microbiology · 2024
    Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Rommel GuevaraInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Belén Prado-VivarInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Sully MárquezInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Erika B MuñozInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Mateo CarvajalInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Juan José GuadalupeLaboratorio de Biotecnología Vegetal, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Mónica Becerra-WongInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Stefanie ProañoInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Rosa Bayas-ReaInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Josefina ColomaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, United States.
Michelle GrunauerEscuela de Medicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Gabriel TruebaInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Patricio Rojas-SilvaInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Verónica BarragánInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Paúl CárdenasInstituto de Microbiología, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
Universidad San Francisco de Quito · ECUniversity of California, Berkeley · US

Funding

American Asian Centers for Arbovirus Research and Enhanced Surveillance (A2CARES)U01AI151788 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Josefina Coloma, Eva Harris · 2020 to 2026
$9.6M
NIAID NIH HHS U01 AI151788
6 · The paper itself

Abstract

SARS-CoV-2 reinfection is defined as a new infection with a different virus variant in an individual who has already recovered from a previous episode of COVID-19. The first case of reinfection in the world was described in August 2020, since then, reinfections have increased over time and their incidence has fluctuated with specific SARS-CoV-2 variant waves. Initially, reinfections were estimated to represent less than 1% of total COVID-19 infections. With the advent of the Omicron variant, reinfections became more frequent, representing up to 10% of cases (based on data from developed countries). The frequency of reinfections in Latin America has been scarcely reported. The current study shows that in Ecuador, the frequency of reinfections has increased 10-fold following the introduction of Omicron, after 22 months of surveillance in a single center of COVID-19 diagnostics. Suspected reinfections were identified retrospectively from a database of RT-qPCR-positive patients. Cases were confirmed by sequencing viral genomes from the first and second infections using the ONT MinION platform. Monthly surveillance showed that the main incidence peaks of reinfections were reached within four to five months, coinciding with the increase of COVID-19 cases in the country, suggesting that the emergence of reinfections is related to higher exposure to the virus during outbreaks. This study performed the longest monitoring of SARS-CoV-2 reinfections, showing an occurrence at regular intervals of 4-5 months and confirming a greater propensity of Omicron to cause reinfections.

Indexed as

COVID-19SARS-CoV-2EcuadorHumansReinfectionRetrospective StudiesCOVID-19genomic epidemiologyreinfectionSARS-CoV-2sequencing

Identifiers

PMID36164552
PMCPMC9507970
OpenAlexW4295027932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.